These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15636683)

  • 1. Angiogenesis-targeted therapies in prostate cancer.
    Lara PN; Twardowski P; Quinn DI
    Clin Prostate Cancer; 2004 Dec; 3(3):165-73. PubMed ID: 15636683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options in hormone-refractory prostate cancer: current and future approaches.
    Harris KA; Reese DM
    Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients with hormone refractory prostate cancer.
    Muthuramalingam SR; Patel K; Protheroe A
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
    Merino M; Pinto A; González R; Espinosa E
    Eur J Cancer; 2011 Aug; 47(12):1846-51. PubMed ID: 21600762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer therapies in advanced prostate cancer.
    Hegeman RB; Liu G; Wilding G; McNeel DG
    Clin Prostate Cancer; 2004 Dec; 3(3):150-6. PubMed ID: 15636681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimetastatic drugs in prostate cancer.
    Chay CH; Cooper CC; Hellerstedt BA; Pienta KJ
    Clin Prostate Cancer; 2002 Jun; 1(1):14-9. PubMed ID: 15046708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis inhibition in the treatment of prostate cancer.
    Madan RA; Dahut WL
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1070-8. PubMed ID: 19719453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis and prostate cancer: important laboratory and clinical findings.
    Cox MC; Permenter M; Figg WD
    Curr Oncol Rep; 2005 May; 7(3):215-9. PubMed ID: 15847713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone refractory prostate cancer: Management and advances.
    Sonpavde G; Hutson TE; Berry WR
    Cancer Treat Rev; 2006 Apr; 32(2):90-100. PubMed ID: 16458434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Angiogenesis in Prostate Cancer.
    Melegh Z; Oltean S
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.